Intellia Therapeutics Announces Positive Phase 1 Trial Data

Intellia Therapeutics ( (NTLA) ) has issued an update.

On June 15, 2025, Intellia Therapeutics announced positive three-year data from the Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress. The trial showed a 98% mean reduction in monthly HAE attack rates with a single dose, and the treatment was well-tolerated with no serious adverse events. The ongoing global Phase 3 HAELO trial has completed screening ahead of schedule, and Intellia plans to present further data in 2025, with a U.S. launch expected in 2027, pending FDA approval.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Spark’s Take on NTLA Stock

According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.

Intellia Therapeutics’ overall stock score is influenced by its robust clinical progress and positive corporate updates, which are offset by financial and valuation challenges common in the biotech industry. The company’s strong R&D pipeline and strategic milestones provide a positive long-term outlook despite near-term financial hurdles.

To see Spark’s full report on NTLA stock, click here.

More about Intellia Therapeutics

Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company leverages gene editing technology to develop novel, first-in-class medicines addressing important unmet medical needs, advancing the treatment paradigm for patients.

Average Trading Volume: 4,213,017

Technical Sentiment Signal: Sell

Current Market Cap: $860.8M

For a thorough assessment of NTLA stock, go to TipRanks’ Stock Analysis page.